



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

15th November, 2024

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Madhava Rao Karicherla has been appointed as Associate Vice President – Formulation Research & Development, Pharma Division, Kothur Unit w.e.f. 15th November, 2024.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are Annexed.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Sl. No.	Name	Mr. Madhava Rao Karicherla
1	Reason for Change in Senior Management	Appointment as Associate Vice President – Formulation Research & Development, Pharma Division, Kothur Unit
2	Date of Appointment & Term of Appointment	15 th November, 2024 & Terms of appointment are as per the Company's Policy
3	Brief profile	<p>Mr. Madhava Rao is an Innovative and Performance-driven Pharmaceutical professional with 20 plus years of rich and extensive experience in global Generic product development, ANDA Filings, Project Life Cycle Management, Operations Management, Procurement Strategy, Quality Management, Budgeting, Team Management, and People Management across Pharmaceutical Industry. He is also having expertise in Pre-formulation and formulation development of Oral Solid Dosage forms (OSD's) (Immediate release and extended-release tablets, DR capsules), liquid orals and parenteral dosage forms (dry powder injections, lyophilized preparations, liquid injections (aqueous and oily). He is also experienced in designing and implementation of first- to- file patent non-infringing strategies for USA and European markets and exposure to Patents and Patent infringement analysis to design patent non-infringing ANDAs for regulated markets.</p> <p>Prior to joining with NATCO Pharma Limited Mr. Madhava Rao worked with Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited and Ranbaxy Research Laboratories.</p> <p>He did Master's of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali, India, 2003 and Bachelor of Pharmacy from Osmania University, India, 2001.</p>
4	Disclosure of relationship between Directors	Not Applicable